search
Back to results

Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 1

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
high GI meal
low GI meal
euglycemic insulin clamp
primed-variable insulin infusion
Sponsored by
Boston Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 1 focused on measuring brain, fMRI, carbohydrate, insulin clamp, intake regulation, overweight, glycemic index

Eligibility Criteria

18 Years - 45 Years (Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 1 diabetes for a minimum of 3 years
  • BMI 20-35 kg/m2
  • Use of insulin pump
  • Willing and able to: Maintain weight and document for duration of the study

Exclusion Criteria:

  • Insulin resistance (current insulin requirement > 1.5 U/kg/d)
  • Insulin requirement < 0.5 unit/kg/day (cut-off for preserved beta-cell function)
  • HbA1C ≥ 8.0%
  • DKA within 2 months
  • Frequent hypoglycemia (BG <50 mg/dl), > 3 times per week
  • Fluctuations in body weight >10% over preceding year
  • Smoking or illicit substance abuse
  • High levels of physical activity (≥60 minutes per day, ≥ 4 days per week)
  • Current weight loss diet
  • Medical problems, medications or dietary supplements that may affect metabolism, insulin action, body weight, appetite, energy expenditure, or gastrointestinal absorption (e.g. celiac disease)
  • Allergies to compounds or intolerance of the liquid meals
  • MRI exclusion criteria
  • Other conditions according to self-report that would prohibit participation based and researcher assessment

Sites / Locations

  • Beth Israel Deaconess Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

high GI meal, euglycemic insulin clamp

high GI meal, fixed insulin infusion

low GI meal, euglycemic insulin clamp

Arm Description

A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.

A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.

A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.

Outcomes

Primary Outcome Measures

Nucleus Accumbens Blood Flow
Cerebral blood flow in the right and left nucleus accumbent was measured by arterial spin labeling (MRI). Blood flow was normalized for whole brain perfusion and corrected for baseline perfusion in the respective brain area and meal order, as per our a priori statistical analysis plan.

Secondary Outcome Measures

Nucleus Accumbens Blood Flow
Cerebral blood flow in the right and left nucleus accumbent was measured by arterial spin labeling (MRI). Blood flow was normalized for whole brain perfusion and corrected for baseline perfusion in the respective brain area and meal order, as per our a priori statistical analysis plan.
Blood Flow in Other Brain Areas Involved in Intake Regulation - Dorsal Caudate
Cerebral blood flow was measured by arterial spin labeling (MRI). Grouped MRI data was visually inspected for postprandial differences between conditions. Blood flow from a cluster contracting the conditions in the right dorsal caudate, just lateral to the nucleus accumbent, was extracted, normalized for whole brain perfusion and corrected for baseline perfusion in the respective brain area and meal order, as per our a priori statistical analysis plan.
Blood Flow in Other Brain Areas Involved in Intake Regulation - Ventrolateral Striatum
Cerebral blood flow was measured by arterial spin labeling (MRI). Grouped MRI data was visually inspected for postprandial differences between conditions. Blood flow from a cluster contracting the conditions in the right ventrolateral striatum, just lateral to the nucleus accumbent, was extracted, normalized for whole brain perfusion and corrected for baseline perfusion in the respective brain area and meal order, as per our a priori statistical analysis plan.
Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation
Cerebral blood oxygen concentration level was measured by resting state functional MRI (rs-fMRI). Seed based analysis was performed with the seed on the right Nucleus Accumbens. Functional connectivity between Nucleus Accumbens and Hypothalamus was assessed through extraction of temporal correlation measures.
Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation
Cerebral blood oxygen concentration level was measured by resting state functional MRI (rs-fMRI). Seed based analysis was performed with the seed on the right Nucleus Accumbens. Functional connectivity between Nucleus Accumbens and Hypothalamus was assessed through extraction of temporal correlation measures. Functional connectivity between Nucleus Accumbens and other brain areas was visually assessed.

Full Information

First Posted
May 11, 2016
Last Updated
May 25, 2021
Sponsor
Boston Children's Hospital
Collaborators
Beth Israel Deaconess Medical Center, Brigham and Women's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02772783
Brief Title
Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus
Official Title
Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
July 2016 (undefined)
Primary Completion Date
May 2018 (Actual)
Study Completion Date
May 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston Children's Hospital
Collaborators
Beth Israel Deaconess Medical Center, Brigham and Women's Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Processed carbohydrates cause rapid changes in blood sugar and have been associated with overeating and obesity. We have shown that test meals high in processed carbohydrate affect brain areas involved in addiction, craving and overeating. It is unknown whether the changes in blood sugar or the associated higher insulin levels mediate this brain activation and its likely adverse effects. Answering this question is important for patients with type 1 diabetes who have elevated risks of obesity and disordered eating: If blood sugar is the causal mechanism, optimal insulin coverage should be protective. If insulin is the causal mechanism, however, a diet high in processed carbohydrate could predispose to overeating and weight gain, as this diet requires higher insulin doses. To disentangle these factors, we will study brain activation and relevant blood markers in 15 men with diabetes. In 4 sessions, we will examine meals with differential carbohydrate properties while giving insulin infusions.
Detailed Description
A total of 15 male participants (age 18-45) with T1DM will be recruited. Participants will be enrolled in the study for a total of 1-3 months, and participate in a pre-test visit and three test visits, each after a 10-12-hr overnight fast. Participants will be instructed to consume their regular, weight maintaining diet between visits. At the pre-test visit, the study director or PI will meet participants, confirm eligibility and obtain informed consent. Participants will receive a low glycemic index (GI) meal with optimal iv insulin coverage using a negative feedback algorithm to maintain euglycemia (euglycemic clamp). Insulin requirement will be quantified. At some time during the visit, participants will present to the BIDMC research imaging facility for a practice MRI session, during which they will undergo a brief imaging sequence to get accustomed to the scanning process and eliminate anxiety as a confounder of imaging data. At each of 3 test visits, one of the following experimental conditions will be applied in a randomized, blinded cross-over design: (a) high GI meal with euglycemic clamp, (b) low GI meal with euglycemic clamp, (c) high GI meal with primed-variable insulin infusion at the rate established during the pre-test visit. After steady state is established, baseline laboratory evaluation and MRI imaging will be obtained, followed by the test meal. Imaging will be repeated at 1 and 4 hours postprandial. Blood samples for pertinent metabolic and hormonal parameters will be obtained every 30 minutes. Each test-visit concludes with a standard weighed meal to quantify ad-libitum intake.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1
Keywords
brain, fMRI, carbohydrate, insulin clamp, intake regulation, overweight, glycemic index

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
high GI meal, euglycemic insulin clamp
Arm Type
Experimental
Arm Description
A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
Arm Title
high GI meal, fixed insulin infusion
Arm Type
Experimental
Arm Description
A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
Arm Title
low GI meal, euglycemic insulin clamp
Arm Type
Active Comparator
Arm Description
A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
Intervention Type
Other
Intervention Name(s)
high GI meal
Intervention Description
High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of ~90 is achieved by using corn syrup as a carbohydrate source.
Intervention Type
Other
Intervention Name(s)
low GI meal
Intervention Description
High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of ~40 is achieved by using uncooked corn starch as a carbohydrate source.
Intervention Type
Drug
Intervention Name(s)
euglycemic insulin clamp
Intervention Description
Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
Intervention Type
Drug
Intervention Name(s)
primed-variable insulin infusion
Intervention Description
A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are > 400 mg/dl or < 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
Primary Outcome Measure Information:
Title
Nucleus Accumbens Blood Flow
Description
Cerebral blood flow in the right and left nucleus accumbent was measured by arterial spin labeling (MRI). Blood flow was normalized for whole brain perfusion and corrected for baseline perfusion in the respective brain area and meal order, as per our a priori statistical analysis plan.
Time Frame
4 hrs postprandial
Secondary Outcome Measure Information:
Title
Nucleus Accumbens Blood Flow
Description
Cerebral blood flow in the right and left nucleus accumbent was measured by arterial spin labeling (MRI). Blood flow was normalized for whole brain perfusion and corrected for baseline perfusion in the respective brain area and meal order, as per our a priori statistical analysis plan.
Time Frame
1 hr postprandial
Title
Blood Flow in Other Brain Areas Involved in Intake Regulation - Dorsal Caudate
Description
Cerebral blood flow was measured by arterial spin labeling (MRI). Grouped MRI data was visually inspected for postprandial differences between conditions. Blood flow from a cluster contracting the conditions in the right dorsal caudate, just lateral to the nucleus accumbent, was extracted, normalized for whole brain perfusion and corrected for baseline perfusion in the respective brain area and meal order, as per our a priori statistical analysis plan.
Time Frame
4 hrs postprandial
Title
Blood Flow in Other Brain Areas Involved in Intake Regulation - Ventrolateral Striatum
Description
Cerebral blood flow was measured by arterial spin labeling (MRI). Grouped MRI data was visually inspected for postprandial differences between conditions. Blood flow from a cluster contracting the conditions in the right ventrolateral striatum, just lateral to the nucleus accumbent, was extracted, normalized for whole brain perfusion and corrected for baseline perfusion in the respective brain area and meal order, as per our a priori statistical analysis plan.
Time Frame
1 hr postprandial
Title
Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation
Description
Cerebral blood oxygen concentration level was measured by resting state functional MRI (rs-fMRI). Seed based analysis was performed with the seed on the right Nucleus Accumbens. Functional connectivity between Nucleus Accumbens and Hypothalamus was assessed through extraction of temporal correlation measures.
Time Frame
4 hrs postprandial
Title
Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation
Description
Cerebral blood oxygen concentration level was measured by resting state functional MRI (rs-fMRI). Seed based analysis was performed with the seed on the right Nucleus Accumbens. Functional connectivity between Nucleus Accumbens and Hypothalamus was assessed through extraction of temporal correlation measures. Functional connectivity between Nucleus Accumbens and other brain areas was visually assessed.
Time Frame
1 hr postprandial
Other Pre-specified Outcome Measures:
Title
Plasma Glucose Level
Description
blood samples will be obtained every 30 minutes
Time Frame
0-4.5 hrs postprandial
Title
Serum Insulin Level
Description
blood samples will be obtained every 30 minutes
Time Frame
0-4.5 hrs postprandial
Title
Serum Fatty Acids
Description
blood samples will be obtained every 30 minutes
Time Frame
0-4.5 hrs postprandial
Title
Plasma Ghrelin
Description
blood samples will be obtained every 30 minutes and analyzed as part of a metabolic hormone panel
Time Frame
0-4.5 hrs postprandial
Title
Plasma GLP-1
Description
blood samples will be obtained every 30 minutes and analyzed as part of a metabolic hormone panel
Time Frame
0-4.5 hrs postprandial
Title
Plasma PYY
Description
blood samples will be obtained every 30 minutes and analyzed as part of a metabolic hormone panel
Time Frame
0-4.5 hrs postprandial
Title
Plasma CCK
Description
analyzed as part of a metabolic hormone panel
Time Frame
0-4.5 hrs postprandial
Title
Plasma Glucagon
Description
blood samples will be obtained every 30 minutes and analyzed as part of a metabolic hormone panel
Time Frame
0-4.5 hrs postprandial
Title
Plasma Leptin
Description
analyzed as part of a metabolic hormone panel
Time Frame
0-4.5 hrs postprandial
Title
Metabolomics
Description
LC-MS/MS methodology using several chromatographic stationary phases for > 400 metabolites
Time Frame
0, 1 and 4 hrs postprandial

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 1 diabetes for a minimum of 3 years BMI 20-35 kg/m2 Use of insulin pump Willing and able to: Maintain weight and document for duration of the study Exclusion Criteria: Insulin resistance (current insulin requirement > 1.5 U/kg/d) Insulin requirement < 0.5 unit/kg/day (cut-off for preserved beta-cell function) HbA1C ≥ 8.0% DKA within 2 months Frequent hypoglycemia (BG <50 mg/dl), > 3 times per week Fluctuations in body weight >10% over preceding year Smoking or illicit substance abuse High levels of physical activity (≥60 minutes per day, ≥ 4 days per week) Current weight loss diet Medical problems, medications or dietary supplements that may affect metabolism, insulin action, body weight, appetite, energy expenditure, or gastrointestinal absorption (e.g. celiac disease) Allergies to compounds or intolerance of the liquid meals MRI exclusion criteria Other conditions according to self-report that would prohibit participation based and researcher assessment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Belinda S Lennerz, MD, PhD
Organizational Affiliation
Boston Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus

We'll reach out to this number within 24 hrs